Three potential takeover targets in psychedelics

Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.

By Kelly Bilodeau • Aug. 4, 2026

Trump has another tariff plan to reshore generic drug production. Will it work?

The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.

By Kelly Bilodeau • Aug. 3, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Specialty pharma has an infrastructure problem, and IT can’t solve it alone

Technology to enable the specialty patient journey is becoming IT's problem, but the fix isn't becoming the expert.

By Danny Sigurdson, Founder and CEO, Courier Health • Aug. 3, 2026

The future of oral drug delivery must be sustainable

How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.

By Lucas Cusin, Global Technical Marketing Manager, Oral Drug Delivery Solutions, Evonik & Thilo Krapfl, Head of Product Line Oral Drug Delivery Solutions, Evonik • Aug. 3, 2026

Why pharma’s record-setting M&A streak is so unique

Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking picture this year.

By Kelly Bilodeau • July 31, 2026

Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision

Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.

By PharmaVoice Staff • July 31, 2026

How Telix landed a $2.1 billion radiopharma deal with Regeneron

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement. 

By Alexandra Pecci • July 30, 2026

Kalshi is expanding online betting in drug R&D — unless detractors can stop it

Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.

By Susanna Vogel • July 28, 2026

Brand-name drug denials are surging, especially for weight-loss

Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to fill them.

By Alexandra Pecci • July 28, 2026

The FDA was all in on AI. Will that change?

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

By Kelly Bilodeau • July 24, 2026

Lilly’s leap into psychedelics; peptides in the spotlight

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs. 

By PharmaVoice Staff • July 24, 2026

Biopharma challenges leaders want to tackle

Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.

By Meagan Parrish • July 23, 2026

Why the FDA’s top spot could sit empty for months

Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving the agency’s long-term initiatives in limbo.

By Susanna Vogel • July 22, 2026

Beyond weight loss: Lilly aims for leadership in brain science

Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.

By Kelly Bilodeau • July 21, 2026

As the Ebola outbreak rages, new treatments are headed into trials. Will they work?

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

By Alexandra Pecci • July 20, 2026

Long days, dinners with copious alcohol, and the hunt for emerging assets in China

Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.

By Meagan Parrish • July 17, 2026

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

By Kelly Bilodeau • July 17, 2026

Biotech funding gap widens despite rebound in VC investment

Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.

By Gwendolyn Wu • July 14, 2026

What policies could last — or could get axed — amid leadership churn at FDA

How new review policies, the use of AI and other recent FDA changes are being impacted by high turnover at the top.

By Kelly Bilodeau • July 10, 2026

What pharma leaders wish they knew on day 1

PharmaVoice checked in with four life sciences executives after they landed a new role. Now they’re looking back on what they learned.

By Alexandra Pecci • July 9, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

Can anyone catch up to Eli Lilly?

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

By Kelly Bilodeau • July 7, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Can pharma sustain its $2T trajectory?

GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.

By Kelly Bilodeau • July 2, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026